



Medicines Breakout Group

**Chair: Professor Ruth Duncan,
Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University**

**Co-Chair: Dr. Hermann Stamm
European Commission Joint Research Centre, Institute for Health and Consumer
Protection (Ispra)**

Brussels, Friday, 3 October 2008



Needs - improve communication/dialogue Aspect 1.

- **Communication scientists/experts to general public**
 - Duty to explain developments of “Nanotechnology” in Medicine in a timely way
 - **Different perspectives**
 - Benefit-risks in communication, and of non-communication
 - What to communicate? Technical details-mechanisms of action?
 - How to communicate uncertainties
 - Building trust while sharing risk-benefit
- Information should not be withheld - early access to information - it should be an interactive process



Needs - improve communication/dialogue Aspect 2.

- **Communication of Scientist to Scientist -Expert to Expert**
 - Definition of status and emerging needs
 - Improve communication across all constituent disciplines -including technical expertise and policy making agencies, regulatory agencies and society....
.....expert to Healthcare Professionals
- **Communication between the medical doctor and the patient**



Who should do what, where, and when to improve communication/dialogue? Aspect 1.

■ **Communication to the General Public**

– examples of good practice

■ **Regulatory Agencies**

- Website information - Readability - lay language
 - Possibility to interact/feedback to the information provider
- Follow-up by the Agency on feedback from public
- Involving patient organisations in decision making bodies

■ **Scientists and Experts**

- Nanodialogues/Nanojuries
- Enabling feedback in policy-making



Who should do what, where, and when to improve communication/dialogue? Aspect 2.

- ***Communication across Scientific Disciplines/ Experts -best practice***
- EC -Safety for Success.....
- Member State Government Policy setting Strategic Advisory Teams
- Other eg.
 - ESF Research Conferences, Summer Schools Workshops
 - Use existing communication lines, nano-specific information



Needs to improve the implementation of the existing legislation ?

■ **Current regulation**

- Medicine and medical device area already well regulated

- No need to re-invent the wheel
- How to deal with borderlines/nano issues?
- How to deal with fast/emerging nano scientific developments

- Medicinal products – medical devices
- New knowledge to be integrated on case by case basis

■ **Integration of different regulatory areas**

- Exchanging best practice
- Exchanging best technical practice



Who should do what, where, and when - means to improve impl. of existing reg.?

■ Regulatory Agencies

- Ongoing review of regulatory practice
- Ensure uniformity of best practice

■ Involvement of patient representatives

- Workshops with patient/healthcare provider organisations
- Involvement of patients prior to product approval
- Encourage website interaction/feedback

This paper was produced for a meeting organized by Health & Consumer Protection DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumer Protection DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.